A Phase 1 interventional study of PN400 in Arthritis, sponsored by POZEN. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-09-05.
Sponsored by POZEN (part of Aralez Pharmaceuticals) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 413 studies in Arthritis with a site in United States — 38 open to participants now, 55 under way, 4 of them phase 3. Arthritis · United States.
Among the 413 studies in Arthritis with a site in United States, this one is the 275th largest by enrollment of the 337 interventional ones that give a count, is one of 18 that started in 2008, is one of 29 in phase 1, and was the 88th registered.
843 studies on the registry are indexed under Arthritis; 118 are open to participants now.
Browse Arthritis studies →38 of the 413 studies in Arthritis with a site in United States are open now. Recruiting first, the newest first:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Margaret L Gourlay, MD, MPH · Sites in United States
Ages 50–64
University of Chicago · Sites in United States
Ages 40+
Faith A. Richardson · Sites in United States
Ages 21–80 · Healthy volunteers
Terry L. Wahls · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 78 Arthritis studies recruiting now, 41 (53%) set no upper age limit and 20 (26%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
413 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 78 · Phase 3 73 · Phase 4 17
First in 1979; this study’s year is marked. 18 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 97 across 599 interventional studies indexed under Arthritis.
Median enrollment 100 across the 337 interventional studies, 134 across the 75 observational. Of the 317 that completed or were terminated, 142 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
186 of 413 have an industry lead sponsor. The 10 most frequent:
This study is registered under POZEN, one of the names counted as Aralez Pharmaceuticals. Under that name alone:
POZEN is the lead sponsor of 27 studies on the registry; none are open to participants now.
Aralez Pharmaceuticals has 5 studies filed under Arthritis — fewer than ten, so there is no comparison to draw.
16 of the studies in Arthritis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05658575Phase 3Olatec Therapeutics, Inc.Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | 2026-12-31 |
| NCT06550024CrannMedSakuraBead Used as Resorbable Embolic for Genicular Artery Embolization | 2026-12 |
| NCT06383585Mayo Clinic3D DL Ozteo in the Detection of Osseous Changes in Patients With Inflammatory Arthritis | 2026-12-10 |
| NCT05666167VA Office of Research and DevelopmentExpanding Exercise Programming for Veterans Through Telehealth | 2026-12-31 |
| NCT06915012First Institute of All MedicinesImpact of Biophoton Therapy on Chronic Severe Arthritis Pain | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 413 studies in Arthritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
We will evaluate the effect of food on the bioavailability of the components of PN400
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
PN400 administered after meal
Drug: PN400
PN400 administered prior to meal
Drug: PN400
PN400 administered prior to meal
Drug: PN400
PN400 followed by fast
Drug: PN400
Drug pages: Naproxen · Esomeprazole
naproxen/esomeprazole
To determine the effects of food eaten at different times on the bioavailability of the components of PN400 following a single oral dose in healthy subjects.
Time frame: 72-hours
To assess the safety and tolerability of PN 400 under fasting and fed conditions.
Time frame: entire study duration
The record gives a start of May 2008, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Naproxen · Esomeprazole